• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Top 5 Multiple Sclerosis Apps for Primary Care Providers

News
Slideshow

A multiple sclerosis diagnosis can leave patients feeling overwhelmed, but these 5 apps can help providers guide patients through diagnosis and treatment. 

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Positive Topline Results on Long-Term Safety Reported for Rocatinlimab in Moderate to Severe Atopic Dermatitis©MichaelVI/stock.adobe.com

Positive Topline Results on Long-Term Safety Reported for Rocatinlimab in Moderate to Severe Atopic Dermatitis

Grace Halsey
September 9th 2025
Article

Rocatinlimab offers promise as a novel T-cell rebalancing therapy that targets the OX40 receptor, with maintenance dosing as infrequently as every 8 weeks.

Weekly Dose Podcast: Psoriasis Drug Success, Intranasal Insulin Insights, and New Data on Vaccines and GLP-1 Use

Weekly Dose Podcast: Psoriasis Drug Success, Intranasal Insulin Insights, and New Data on Vaccines and GLP-1 Use

Sydney Jennings
September 5th 2025
Podcast

This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension / image credit ©Sundry Photos

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension

Grace Halsey
September 9th 2025
Article

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Sydney Jennings
August 28th 2025
Podcast

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds

Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds

Sydney Jennings
September 8th 2025
Article

Analysis presented at AHA Hypertension 2025 showed fewer than 6% of US adults use salt substitutes, despite their potential to improve BP control.

FDA OKs Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis: Daily Dose / image credit: ©New Africa/AdobeStock

FDA OKs Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis: Daily Dose

Sydney Jennings
September 8th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.